Arcoxia
5 customer reviewsArcoxia is a selective COX-2 NSAID containing etoricoxib. It is used in adults for inflammatory joint pain and short-term acute pain. It helps by reducing prostaglandins that drive pain, swelling, and stiffness.
What is it?
Arcoxia is a non-steroidal anti-inflammatory drug (NSAID) from the group called selective COX-2 inhibitors. Its active ingredient, etoricoxib, is designed to block cyclooxygenase-2 (COX-2), an enzyme the body uses to produce inflammatory prostaglandins. When prostaglandins drop, pain and swelling usually ease, and joint movement often feels less restricted.
Arcoxia aims to spare COX-1 more than non-selective NSAIDs do. COX-1 supports protective stomach lining prostaglandins, so COX-2 selectivity can mean fewer stomach-ulcer problems for some people compared with classic NSAIDs, though it does not remove GI risk completely and it does not remove cardiovascular risk [1].
Arcoxia is taken as pills, and for many adults the effect is felt within hours and can last up to 24 hours, which is why once-daily dosing is commonly used in practice.
Composition
Etoricoxib is the active pharmaceutical ingredient in Arcoxia. It works by selectively inhibiting COX-2, the main cyclooxygenase isoenzyme induced during inflammation. This reduces prostaglandin production at inflamed tissues, which is why pain and swelling tend to fall.
Because etoricoxib is more COX-2 selective, it has less direct inhibition of COX-1 than many older NSAIDs. COX-1 is linked to gastric mucosal protection and platelet effects, so COX-2 selectivity is one reason some patients report fewer stomach symptoms when they switch from non-selective NSAIDs.
Arcoxia on this page is offered in 60 mg, 90 mg, and 120 mg strengths as pills.
How to use?
Dose selection is condition-based and should be set by the prescriber; doctors choose the lowest dose for the shortest time that controls symptoms. Arcoxia is typically taken once daily, with or without food.
Common dosing patterns used in adult practice:
- Osteoarthritis: 60 mg once daily is often used.
- Rheumatoid arthritis / ankylosing spondylitis: 90 mg once daily is a common regimen.
- Acute pain or gout flare: 120 mg once daily may be used short term (commonly up to 8 days).
Swallow the pill with water. Taking it at the same time daily helps avoid missed doses and “double-dosing” the next day.
Do not stack NSAIDs.
If a dose is missed, take it when you remember on the same day. If it’s close to the next dose, skip the missed one and return to the usual schedule.
How does it work?
• Oral route only: Swallow the tablets whole with water.
• Dose: 60 mg once daily for osteoarthritis, 90 mg once daily for rheumatoid arthritis, 60 mg once daily for ankylosing spondylitis, and 90 mg once daily for acute gout pain; some patients may need 120 mg once daily for short-term acute pain.
• Timing: Take the tablet at the same time each day; it can be taken with or without food.
• Duration: Use the lowest effective dose for the shortest possible time; acute pain is usually treated for up to 8 days, while chronic joint conditions are used according to medical advice.
• Route/form: Oral tablets only; do not crush or chew.
Indications
Arcoxia is prescribed to relieve pain and inflammation in several conditions where prostaglandins drive symptoms. The goal is symptom control: less pain, less swelling, less stiffness, better mobility. For some patients, that makes daily movement easier, but it does not treat the underlying disease process.
Typical uses include:
- Osteoarthritis: helps with mechanical joint pain plus inflammatory “flare” days, improving function during walking and stairs.
- Rheumatoid arthritis: reduces inflammatory pain and morning stiffness; it is not a disease-modifying treatment.
- Ankylosing spondylitis: can ease spinal pain and stiffness so daily movement and sleep are less disrupted.
- Gout: used for short courses during acute gout attacks when pain and swelling peak.
- Acute pain: may be used short-term for painful inflammatory states, including post‑procedure pain when a clinician chooses a COX-2 selective NSAID.
Comparison
Arcoxia sits in the NSAID family, with COX-2 selectivity as its defining feature. It often fits patients who want once-daily anti-inflammatory coverage or who struggled with dyspepsia on non-selective NSAIDs, while still needing strong pain control.
| Option | How it compares | Typical use case |
|---|---|---|
| Arcoxia (etoricoxib) | COX-2 selective NSAID; once-daily effect; still carries cardiovascular and kidney warnings | Inflammatory joint pain, gout flares (short course), selected acute pain |
| Non-selective NSAIDs (ibuprofen, naproxen, diclofenac) | Inhibit COX-1 and COX-2; often cheaper class-wide; GI irritation may be more common | Broad pain indications; short courses; some options suitable at OTC doses |
| Paracetamol (acetaminophen) | Not an NSAID; minimal anti-inflammatory action; generally gentler on stomach | Mild pain or add-on therapy when inflammation is not dominant |
Clinicians choose based on your risk profile, not just pain score. If cardiovascular risk is high, many prescribers avoid COX-2 inhibitors and minimise NSAID exposure generally, using non-NSAID strategies where possible.
Contraindications
- Allergy to etoricoxib or NSAID-type allergy reactions (including aspirin-triggered asthma or severe rash)
- Active stomach or duodenal ulcer, or a history of GI bleeding linked to NSAIDs
- Severe heart failure, uncontrolled hypertension, ischemic heart disease, or prior stroke/other cerebrovascular disease
- Severe kidney failure
- Severe liver impairment
- Pregnancy or breastfeeding
- Age under 16 years
Not recommended for
Arcoxia is not a good fit if you have a history of heart disease, stroke, uncontrolled blood pressure, stomach ulcers, kidney problems, or severe liver disease. It is also not suitable during pregnancy or breastfeeding, and it is not for children under 16.
If you already use blood thinners, aspirin, diuretics, ACE inhibitors, ARBs, lithium, methotrexate, or another NSAID, you need a doctor to check the risk first.
Side effects
Most side effects with Arcoxia look like “NSAID class effects,” with a COX-2 selective profile. Headache and dizziness can happen. So can indigestion, nausea, and abdominal discomfort. Swelling of ankles or feet can occur from fluid retention, and blood pressure can rise, even in patients whose readings were usually fine before.
Serious risks are uncommon, yet they matter because they can be life-changing:
- Cardiovascular events (heart attack, stroke) are a known NSAID risk and become more relevant with higher dose and longer duration.
- Gastrointestinal bleeding/ulceration can still occur, especially with past ulcer history, alcohol excess, smoking, or combined medicines that thin the blood.
- Kidney stress may show up as reduced urine output, sudden swelling, or worsening blood pressure control.
- Liver irritation can occur, seen as elevated liver enzymes or symptoms like unusual fatigue, dark urine, or yellowing of eyes.
Stop and seek urgent assessment for chest pain, sudden shortness of breath, one-sided weakness, black stools, vomiting blood, or facial swelling with breathing trouble.
Blood pressure changes are easy to miss.
Common mistakes
These are the patterns pharmacists see repeatedly, and they explain many “sudden” side effects.
- Taking Arcoxia with another NSAID (ibuprofen, diclofenac, naproxen) for extra pain relief. This increases GI bleed risk and kidney stress without adding much benefit.
- Using it at the highest strength for long periods because it “worked once for a flare.” High dose and long duration raise cardiovascular risk.
- Ignoring blood pressure drift. NSAIDs can push readings up, and patients often notice only when headaches or ankle swelling start.
- Combining with dehydration (long outdoor days, fasting, gastroenteritis). Kidneys are more sensitive then, and NSAIDs can tip the balance.
- Treating gout flares but skipping urate management. Pain improves, then the next flare returns, and NSAID exposure accumulates without addressing uric acid.
Small changes prevent big problems. Keep the regimen simple and time-limited when possible.
Doctor opinions
In clinical practice, doctors often reserve Arcoxia for patients who need strong anti-inflammatory pain control with once-daily convenience, or for those who had troublesome dyspepsia on non-selective NSAIDs. Rheumatology and orthopaedic clinics also use it when night pain and morning stiffness are dominant symptoms, since 24‑hour coverage can improve sleep continuity.
Prescribers are usually strict about cardiovascular screening. A history of ischemic heart disease, stroke/TIA, uncontrolled hypertension, heart failure, or significant peripheral arterial disease changes the risk–benefit calculation fast, even when the pain relief is excellent. Many clinicians also review kidney function and diuretic/ACE-inhibitor use before choosing etoricoxib, because NSAIDs can destabilize renal perfusion in vulnerable patients.
One more real-world observation: if a patient needs an NSAID daily for weeks, clinicians often ask, “What’s the plan for the underlying condition?” Arcoxia treats symptoms; it doesn’t slow rheumatoid arthritis joint damage, and it won’t dissolve urate crystals in gout.
Frequently asked questions
Pain relief is often felt within a few hours, with anti-inflammatory benefit building over the next days if inflammation is a big driver of symptoms. Many patients notice the biggest functional change in morning stiffness by day 2–3 rather than after the first dose. EMA safety reviews describe etoricoxib as a once-daily COX-2 inhibitor with sustained effect that supports this dosing pattern [3].
Long-term daily NSAID therapy is usually a “planned decision,” not an autopilot refill. Doctors weigh symptom control against risks like hypertension, edema, kidney stress, and cardiovascular events, and they often aim to step down the dose once the flare settles. WHO resources on medicines safety and pharmacovigilance emphasise reporting and reassessing adverse effects during ongoing therapy, which fits long-term NSAID management in real life [4].
COX-2 selective NSAIDs can increase blood pressure and fluid retention, and they are linked to cardiovascular risk that rises with higher doses and longer courses. If you already have ischemic heart disease, prior stroke, uncontrolled hypertension, or heart failure, clinicians typically avoid Arcoxia and choose a different pain plan. MOHAP patient safety messaging in the UAE places strong emphasis on cardiovascular comorbidities when using NSAIDs, because symptoms like ankle swelling may be the first warning sign.
Both treat pain and inflammation, yet ibuprofen is a non-selective NSAID, while Arcoxia (etoricoxib) is a selective COX-2 inhibitor. COX-2 selectivity can reduce COX-1 related stomach irritation for some patients, though ulcer/bleeding risk can still occur and heart/kidney risks remain. Reviews from regulatory assessments describe COX-2 inhibitors as a distinct NSAID subgroup with different tolerability trade-offs rather than “better in all ways”.
Some patients take low-dose aspirin for cardiovascular protection and still need anti-inflammatory pain treatment. The combination can be used only when a prescriber decides the benefits outweigh the bleeding risk, and it often comes with extra GI protection and monitoring for black stools or persistent indigestion. WHO pharmacovigilance principles highlight that “common” combinations still deserve active monitoring when they raise harm risk, which applies to NSAID-plus-aspirin regimens [5].
Arcoxia is commonly used when osteoarthritis pain has an inflammatory component: swelling, warmth, night pain, or a flare after overuse. It can help pain control so you can keep moving, which protects function and reduces deconditioning. NICE osteoarthritis guidance supports NSAIDs as an option for symptom relief when used at the lowest effective dose and with attention to GI and cardiovascular risk factors.
Front view
Side view
Back view
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (9.4x4.3x0.3 in. or 24x11x0.7 cm) and its contents cannot be seen.
Arcoxia — Comparison with alternatives
Arcoxia Current
Deflazacort Best price
Humira
Rumalaya
Shallaki Best rated
Reviews and Experiences
Sources
- European Medicines Agency (EMA) (2024). Arcoxia (etoricoxib): Summary of Product Characteristics (SmPC). ↑
- MOHAP (Ministry of Health and Prevention, UAE) (2023). Medication safety information: Non-steroidal anti-inflammatory drugs (NSAIDs). ↑
- European Medicines Agency (EMA) (2024). Etoricoxib: European public assessment report and product information. ↑
- World Health Organization (WHO) (2022). Pharmacovigilance: ensuring the safe use of medicines. ↑
- NICE (National Institute for Health and Care Excellence) (2022). Osteoarthritis in over 16s: diagnosis and management (NG226). ↑